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Abstract
Objectives: This is a critical review of anti-phospholipid antibodies (aPL). Most prior reviews
focus on the aPL syndrome (APS), a thrombotic condition often marked by neurological
disturbance. We bring to attention recent evidence that aPL may be equally relevant to non-
thrombotic autoimmune conditions, notably, multiple sclerosis and ITP.
Organization: After a brief history, the recent proliferation of aPL target antigens is reviewed.
The implication is that many more exist. Theories of aPL in thrombosis are then reviewed,
concluding that all have merit but that aPL may have more diverse pathological consequences than
now recognized. Next, conflicting results are explained by methodological differences. The lupus
anticoagulant (LA) is then discussed. LA is the best predictor of thrombosis, but why this is true is
not settled. Finally, aPL in non-thrombotic disorders is reviewed.
Conclusion: The current paradigm of aPL holds that they are important in thrombosis, but they
may have much wider clinical significance, possibly of special interest in neurology.
Background
This manuscript critically compares the many theories
and concepts of anti-phospholipid antibodies (aPL) as
they pertain to the antiphospholipid syndrome (APS) and
other clinical conditions where they occur. This review is
not primarily concerned with clinical diagnosis and man-
agement, except peripherally. Although the topic of aPL
has been reviewed many times, this review was inspired
by findings in our laboratory and others suggesting that
aPL may play roles in a variety of disorders apart from
APS, not necessarily thrombotic.
According to Eng [1] and others, it was Pangborn who in
1941, following Wasserman's test for syphilis in 1903,
identified an acidic phospholipid (PL) as the apparent tar-
get antigen of the test, specifically, cardiolipin (CL). CL is
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named for the bovine heart muscle from which it was
obtained, heart being rich in mitochondria, a main source
of CL. In 1952, Conley and Hartmann first described the
lupus anticoagulant (LA), later interpreted as a conse-
quence of aPL, in association with a hemorrhagic diathe-
sis [2]. However, this and other early clinical observations
were later overshadowed by frequent findings of throm-
bosis associated with positive anti-CL (aCL) test, leading
to recognition of the aPL syndrome (APS) in the 1980s by
Harris et al [3,4] and by Hughes et al [5], originally called
anticardiolipin (aCL) syndrome, now sometimes Hughes'
syndrome.
Although diagnostic criteria vary somewhat depending on
sources, APS is generally defined by a repeatedly positive
test for one or more aPL in conjunction with thrombosis
or recurring pregnancy loss [6-13]. It is often accompa-
nied by thrombocytopenia, episodic neurological distur-
bances [14], and/or numerous other clinical
manifestations [15]. APS may be secondary to other
underlying conditions, notably systemic lupus erythema-
tosus (SLE); otherwise, in the absence of other disorders is
known as primary APS (PAPS). In its most life-threatening
form, it is known as catastrophic APS (CAPS). In patients
with CAPS occlusion of small blood vessels leads to multi-
organ failure. Many reviews of APS with focus on clinical
manifestations and management, laboratory methodolo-
gies, and hypotheses to account for the association
between aPL and thrombosis exist [16-22]. However, as
stressed in this review, many uncertainties remain.
What are aPL and how are they measured?
Originally, aPL were defined as antibodies reacting to car-
diolipin (CL) but for reasons discussed below, no widely
accepted definition of aPL any longer exists. They are
measured by two distinct kinds of tests, solid-phase for
particular aPL, and coagulation-based for LA. The former
is usually an enzyme-linked immunosorption assay
(ELISA), consisting in outline of adding a sample of
patient serum or plasma to a plastic well coated with some
particular PL or mixture of PLs, with or without a specific
protein cofactor (see below), then measuring how much
patient immunoglobulin (Ig) is captured by adding an
anti-human IgG, IgM, or IgA conjugated with an enzyme
that generates a colored product. Despite its simplicity,
this procedure is subject to many subtle variations which
can grossly affect results, discussed later. In contrast, LA
are detected by the prolonged time required for coagula-
tion of the patient's plasma relative to normal plasma in a
test designed to be sensitive to PL. Most commonly, the
dilute Russell viper venom time (dRVVT) is used. It is
widely believed that the prolongation is caused by an aPL
occupying sites on the PL which are required for binding
the coagulation factors, thereby prolonging the time. The
LA is discussed later.
Protein cofactors and definition of aPL
According to Roubey [16], three groups independently in
1990 demonstrated that a positive ELISA test for aCL
depended on a protein cofactor, β2-glycoprotein-I (β2GPI)
[23-25]. This had gone unnoticed because β2GPI is
present in most ELISA methods, either in the bovine or
other animal serum commonly used for dilutions and/or
for blocking the plate against non-specific binding, or in
the test serum or plasma. The requirement for β2GPI can
be shown by using purified Ig and excluding other sources
of β2GPI. As a result, it was often argued that anti-β2GPI is
equivalent to aCL [26-29] or is even a surrogate for aPL
generally [30]. Among the diagnostic criterion of APS has
been the presence of β2GPI-dependent aCL [9]. Since
then, many additional aPL cofactors have been identified,
reviewed below. This has resulted in the widely held opin-
ion that all clinically relevant aPL are directed against pro-
tein target antigens rather than any particular pure PL. If
so, the term aPL is an outmoded misnomer [31]. Thus,
some authors place aPL in quotation marks to indicate the
fallacy [32]. Accordingly, the implicit working definition
of aPL now appears to be an antibody that targets a PL-bind-
ing protein [31-33]. The aPL may react preferentially with
the PL-bound form, or may bind to the free antigen in
plasma as an immune complex (IC) to potentiate binding
to a given PL.
Do all clinically relevant aPL target proteins?
On the other hand, it is known that antibodies reacting to
pure PL (no protein cofactor requirement) do occur in
many infectious diseases, classically in syphilis but also in
leprosy, leishmaniasis, malaria, Epstein Barr virus, hepati-
tis C virus and HIV, e.g. [34,35]. These are spoken of as the
infectious disease type of aPL, and are often said to be
non-pathogenic in themselves and thus clinically irrele-
vant. Partly for this reason, at least one updated criterion
for APS diagnosis has dropped the requirement for aCL
testing entirely [36]. However, Nash et al found that omit-
ting classical aCL assay caused 25% of APS patients to be
missed [37], and therefore urged that aCL testing be
retained. Two commentaries on that article concur
[38,39] and cite additional reasons.
More generally, the view that all clinically relevant aPL are
directed against proteins has been challenged by a
number of authorities [40-43]. To the examples cited by
those authors we may cite the study of von Landenberg et
al [44] in which an IgG antibody was cloned from B cells
of each of two patients, one from APS with thrombosis
and one from SLE without thrombosis, both of which
reacted with CL yet showed no requirement for any pro-
tein in normal serum. Sorice et al [45] gave evidence that
aCL and anti-β2GPI are distinctly different antibodies, as
did Forastiero et al. [27]; but the operative question
debated is whether they are "clinically relevant". FindingsJournal of Neuroinflammation 2009, 6:3 http://www.jneuroinflammation.com/content/6/1/3
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concerning aCL in HIV further emphasize uncertainties
about protein cofactor-independent aPL [46] (discussed
later). McIntryre et al. provide criteria for distinguishing
protein-dependent and -independent aPL [42]. More
recently, biosensor analysis looks promising for clarifica-
tion [47].
There is another and quite different justification for con-
tinued use of the term, aPL. Many laboratories, including
ours, routinely test patients against a panel of pure PL. If
positive, it is most likely that an antibody against some
PL-binding protein in serum is being detected. However,
since the identity of that putative protein is unknown,
there is little choice but to speak of it as aPL+.
Survey of the antigens (or "cofactors")
Table 1 lists most of the aPL target antigens commonly
recognized and several that are less well recognized as
such, although meeting the above definition [48-68].
They are listed in groups from the most well-recognized
and studied at top to less familiar ones at bottom.
Anti-β2-glycoprotein I (anti-β2GPI)
As already mentioned, anti-β2GPI has been equated with
aCL, so that β2GPI (a.k.a. apolipoprotein H) became the
most widely accepted and studied antigen relevant to APS
[26,29,32]. However, several later studies found only a
weak association between anti-β2GPI and thrombosis
[69,70], and this is the main reason why the aCL or β2GPI-
dependent aCL test has been dropped as a criterion of APS
[36,70]. On the other hand, several studies have shown a
strong association provided anti-β2GPI is at very high titer
[71-73]. The role of anti-β2GPI in the LA test is reviewed
later.
Despite the weak association, β2GPI has been the main
focus of theories to account for APS [22], discussed later.
Evidence suggests that pathogenic anti-β2GPI are limited
to specific epitopes, especially the amino terminal
(domain 1) [74-76]. The natural function of β2GPI is
unclear but it may contribute to regulating fibrinolysis
[77] and platelet function [78]. β2GPI co-purifies with
thrombospondin from platelets [79]. It exhibits modest
anticoagulant effects [80-83] which are augmented when
bound to antibody [11]. However, Pengo has indicated
that anti-β2GPI can have either anti- or pro-coagulant
effects [84]. Arvieux found that oxidation of β2GPI caused
either enhanced or decreased binding to Ig: 10 of 20
patients enhanced, 10 decreased [85].
One leading theory to account for its thrombogenicity is
that by binding to PL surfaces, it interferes with the anti-
coagulant protein C system [86]. This popular theory has
several variants. Roubey listed six variant theories for the
procoagulance of β2GPI as of 1994 [32], all seeming via-
Table 1: Antigens of antiphospholipid antibodies
Antigen References
Group 1. Best established & studied
β2GPI Many, e.g. 29, 48,49
Prothrombin Many, e.g. 8, 98, 50
Protein C, S Many, e.g. 93
Annexin V Many, e.g. 11, 123,124
Group 2. Also accepted but less studied
Thrombin 141
Annexin 2 130, 140
Complement C4, FH 131–133
Kininogens 31, 51,52,143
Kallikrein-related 52,133
FVII/FVIIa 135
Antithrombin III 137,138
Group 3. Pure phospholipids
Cardiolipin (CL) Many, e.g. 46
PE Many, e.g. 31
PS, PC, etc. Many, e.g. 53
Oxidized CL 54,55
Oxidized LDL, other PL. 56–58,147,148
Group 4. Often or sometimes included
Plasmin 128
Tissue factor (TF) 134
TF path. inhibitor (TFPI) 130, 309
TPA 60,129
Platelet activating factor (PAF) 153
CD40/CD40L 154
Group 5. Associated or candidate aPL
CD36 157,158Journal of Neuroinflammation 2009, 6:3 http://www.jneuroinflammation.com/content/6/1/3
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ble.  β2GPI and anti-β2GPI have been localized to late
endosomes in cytoplasm as well as the endothelial cell
surface [87]. Since the literature on β2GPI is large and is
well summarized in reviews cited above, it is not further
discussed here.
Anti-protein C, S (aProtC, aProtS)
These proteins, together with thrombomodulin, protein C
inhibitor, and the endothelial protein C receptor (EPCR),
constitute a vital natural anticoagulant system [88,89].
Deficiency of protein S, for example, is both a risk factor
and an explanation for thrombotic events, either familial
[90] or by acquired Ab [91], or by other causes [92]. The
FV Leiden mutation is a risk factor by making FVa resistant
to inactivation by activated protein C. Accordingly, aPL
against ProtC and/or ProtS have been proposed to
account for or contribute to thrombosis in APS [93]. It has
been shown that β2GPI enhances the function of ProtS
[94], suggesting that anti-β2GPI impairs the function of
ProtS. However, these Ab are less common than anti-
β2GPI in most studies of APS. Bick and Pegram [95] pro-
vide a survey of the many kinds and causes of defects of
ProtC and ProtS, including aPL. Duchemin et al detected
LA in 85% of a group of 17 children with varicella, and
aProtS was present in 75% of them, and thrombosis in
24%, all LA+ [96]. In a large study by Nojima et al, neither
aProtS nor aProtC was associated with arterial thrombosis
but aProtS exclusively associated with venous thrombosis
(p = 0.003) while anti-β2GPI had no such association
[97].
Anti-prothrombin (aPT)
The majority of reports and reviews now discount the clin-
ical value of assay for aPT [69,98,99]. At the same time,
most concur that its wide prevalence and intriguing rela-
tionships warrant further study. Pengo et al found strong
association of thrombosis with anti-β2GPI but not with
aPT and conclude that aPT is not a marker of thrombosis
[100]. Indeed, it has been reported that aPT often has a
hemorrhagic diathesis [101]. Conversely, Pasquier et al
found significant association between venous throm-
boembolism (VTE) and aPT but not with anti-β2GPI or
other assays in their study. However, after patients were
stratified by additional risk factors; they concluded that
aPT screening has little value [102]. Of interest, however,
is that aPT strongly correlated with aProtC and aProtS
[100]. On the other hand, Vaarala et al found good asso-
ciation of aPT with myocardial infarcts in middle-aged
men [103]. A review of aPT [8] suggests that interest in aPT
stemmed, in part, from its occurrence in 75% of LA-posi-
tive patients [104] (see later on LA). Galli et al found that
aPT are heterogeneous [105].
Atsumi et al [106] confirmed that aPT are heterogeneous
(as are most aPL) and that the clinical relevance of aPT
depends on the method of detection. For example, the
complex of aPT with phosphatidylserine (aPT/PS) was
associated with thrombosis but aPT itself was not. This
highlights the importance of methodologies, discussed
later. They, too, confirmed that aPT/PS correlates closely
with LA. Donohoe et al explored variations of aPT meth-
ods and found conditions where aPT IgM, but not IgG,
significantly associated with thrombosis [107]. Thus, aPT
may indeed have real clinical significance but only if
assayed in certain ways, and includes IgM assay. The
review cited above [8] concludes cautiously, and notes
that aPT occurs in several inflammatory disorders besides
APS [108]; but this is true of many aPL.
Anti-annexin V (aAnV)
AnV, a calcium-dependent PL membrane-binding pro-
tein, was first identified in abundance in placenta, result-
ing in it being called placental anticoagulant protein 1.
Other synonyms include lipocortin, anchorin, calphobin-
din and vascular anticoagulant alpha [109]. Otherwise, its
function is not clear, but it does act like an ion channel
[110]. It is widely distributed but at lower concentrations
than in pregnancy. AnV binds specifically to anionic PL,
especially PS, and therefore acts in vitro as an anticoagu-
lant by competing for sites on PL membranes where the
coagulation factors normally assemble into active com-
plexes (prothrombinase and tenase) and so mimics the LA
effect [111,112]. Fluorescent AnV is widely used to iden-
tify PS-positive apoptotic cells, procoagulant microparti-
cles, and activated cells [113-117]. It has been shown that
PS triggers a specific receptor for phagocytosis [118],
although, as noted in that commentary, details are com-
plex.
Antibodies to AnV (aAnV) are widely accepted as aPL in
most reviews, e.g. [119]. In one study, frequency of aAnV+
in SLE, APS and other prothrombotic disorders was the
Thrombomodulin 32
EPCR 61,63
Phospholipase A2 156
Group 6. Implicit under definition
FVIII Many, e.g. 63–66,141
FX 16
FXI 52,67,155
FXII 68,161
Table 1: Antigens of antiphospholipid antibodies (Continued)Journal of Neuroinflammation 2009, 6:3 http://www.jneuroinflammation.com/content/6/1/3
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same as anti-β2GPI about 30%, and was the only signifi-
cant risk factor for recurrent fetal loss, p = 0.01 [97]. Since
AnV is believed to be an important anticoagulant during
pregnancy, Donohoe et al offer evidence that anti-β2GPI,
along with blockade of AnV by aAnV, may explain APS-
associated miscarriage [120]. Rand et al had earlier pro-
posed that aPL caused pregnancy loss by reducing levels of
AnV [121]. The association of aAnV with miscarriage has
been observed frequently, recently by Galli et al [122].
Anti-AnV has been studied extensively in SLE [123-125]
including in comparison with other aPL [97]. Like most
aPL, aAnV has been noted in other conditions, notably in
rheumatoid arthritis, where it may play a role in pathol-
ogy [126,127]. In that connection, it may be added that
variants of AnV occur, even within a single tissue such as
cartilage [128], which may help explain discordant find-
ings. Binding of AnV is sensitive to the structure of the PL
surface [129]. Zhang et al reported that endothelial activa-
tion induced by aPL is mediated by AnV [130]. Several
workers have proposed a role of aAnV in LA activity, dis-
cussed later.
Group 2 of Table 1
No attempt is made to review all the aPL listed. Group 2
includes those commonly cited in review articles but
which are less well studied than Group 1. Anti-kininogens
are discussed below with anti-phosphatidyl ethanolamine
(aPE). Kertesz et al found anti-complement factor H
(aCFH) competitive with anti-β2GPI for CL binding [131].
Similarly, Arnout detected aCFH along with anti-β2GPI in
all of 5 plasma samples [132], and this was confirmed
again by Rampazzo et al, who also found anti-C4 (aC4)
[133]. Hemolytic uremic syndrome (HUS) of the non-E.
coli type is thought to be mediated by aCFH, e.g. [134].
Anti-factor VII/VIIa (aFVII) was regularly found in aPL
ELISA assays by Bidot et al [135]. Later, Minagar et al
found a close association of aFVII with specific clinical
states in multiple sclerosis [136], as discussed later.
Antibodies to antithrombin III (aAT-III) in APS patients
were reported by Kolev et al [137], and were found to be
associated with anti-heparin Ab in APS [138], i.e.,
heparin-induced thrombocytopenia (HIT). Arnout has
drawn interesting parallels between aPL and HIT/anti-
platelet factor 4 [139]. The recent discovery of anti-
annexin 2 in 40% of APS patients [140] aroused much
interest, as did the finding of anti-thrombin Ab [141,142].
Group 3 of Table 1: Pure phospholipids (PL)
Aside from CL, the most commonly tested PL are phos-
phatidylcholine (PC), phosphatidylserine (PS), and phos-
phatidyl ethanolamine (PE), sometimes in mixtures; e.g.
[119,135]. It appears that the protein cofactors responsi-
ble for positive aPE are predominately kininogens or
kininogen-IC [143]. McIntyre et al proposed a novel
hypothesis of aPL-dependent thrombosis on that basis
[31]. Sanmarco et al reported a strong association of aPE
IgM, but not other aPL, with APS and other unexplained
thromboses [144]; however, an earlier report found that
aPE was the only aPL tested that was not associated with
thrombosis [145]. This further illustrates frequent discrep-
ant findings. In a study of LA+ patients, who were divided
into drug-induced vs. auto-Ab associated, aPE was 95%
positive in the autoimmune groups (SLE, APS) [146].
As referenced in Table 1, much interest has centered on Ab
to oxidizied PL (aOxPL) or oxidized lipoproteins such as
low-density lipoproteins (LDL) in relation to thrombosis.
This topic has extensive literature and we will only give
some examples. Wu et al [147] followed 2322 subjects,
age 50 or older, for up to 20 years. The investigators found
that anti-oxLDL IgA correlated closely with aCL (p <
0.0001) but IgM and IgG had weak or no association,
respectively. Steinerova et al [148] measured anti-oxPL in
infants and observed that breast-fed babies, during the
first 3 months, had much lower levels (p < 0.001) and less
DNA breaks than those not breast-fed. As noted later, CL
easily oxidizes in air so that many reports actually meas-
ure aOxCL, not aCL.
Group 4 of Table 1
These are PL membrane-binding proteins against which
auto-Ab are known to occur, and therefore meet the defi-
nition of aPL, yet are not commonly listed in reviews of
aPL, even though their binding properties suggest they
may be detected, if unwittingly, in aPL assays against pure
PL. However, a recent aPL review [22] includes Ab to plas-
min [149] and to tissue plasminogen activator (aTPA)
[150]. Tissue factor pathway inhibitor (TFPI) associates
with many PL, and high-titer aTFPI was reported in APS
[151]. (It was reported that anti-β2GPI suppresses TFPI
activity [152].) Certainly aTFPI is a candidate for pro-
thrombotic effects but is rarely tested for.
Anti-platelet activating factor (aPAF) has also been
reported in APS [153], as has anti-CD40 [154]. Tissue fac-
tor itself (TF), which is known to be carried on PS-express-
ing cell-derived microparticles, is also capable of eliciting
auto-Ab, and aTF was listed as an aPL in at least one review
[33], citing De Groot [155]. According to De Groot's
review, anti-phospholipase A2 was also regarded as an
aPL, by Vermylen and Arnout, 1992; and see [156].
Group 5 of Table 1
These are agents which do not fit the definition since they
are normally membrane-bound, not free in plasma, yet
have been listed in relation to aPL, if not aPL per se.
Roubey [32] included anti-thrombomodulin (aTM) and
anti-heparan sulfate proteoglycans (aHSP) "because ofJournal of Neuroinflammation 2009, 6:3 http://www.jneuroinflammation.com/content/6/1/3
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their respective roles in the control of thrombosis". Like-
wise, antibodies to CD36 (a.k.a. platelet glycoprotein IV)
have been implicated in APS [157,158] and cited in aPL
review [16], as has aEPCR, which can exist in soluble
form. Anti-ADAMTS13 [159], believed responsible for
most cases of TTP, is also prothrombotic; but these clearly
fall outside the definition of aPL.
Group 6 of Table 1
These are PL-binding coagulation factors known to some-
times elicit autoantibodies but are not usually recognized
as aPL. This is inconsistent with recognition of anti-pro-
thrombin (aPT), anti-thrombin, anti-protein C, anti-FVII,
anti-kininogens and anti-tPA as bona fide aPL. They can
be detected in some aPL assays against pure PL if plasma
is used and Ca2+present. Some have been implicated in
APS. For example, Gallimore et al, after studies to measure
FXII deficiency in the confounding presence of aPL [160],
later recognized that anomalous effects were actually due
to anti-FXII, leading to the discovery that anti-FXII is spe-
cifically associated with recurrent fetal loss [161].
Deficiency of FVIII is the hallmark of hemophilia A but
efforts to correct it with FVIII concentrates are plagued by
the rise of anti-FVIII in response. Of interest, the anti-FVIII
is often associated with aPL/LA, as in the report of Nuss et
al, confirming prior reports in finding that of 6 children
with aFVIII, all had positive LA on at least one visit [162]
(see later on LA). One may suspect that the reason for
excluding aFVIII from lists of aPL is not because of defini-
tion of aPL, but is because it is associated with bleeding,
not thrombosis.
Conclusion
This section has called attention to the large number of
aPL now implicated in APS. It is likely that many more
await identification. Second, it illustrates some inconsist-
encies among reports, discussed later. Third, it appears
that the definition or concept of aPL has been guided by
the putative association of aPL with thrombosis (APS).
Although that is a legitimate concern in view of much evi-
dence, we must not be blinded to the likelihood that some
aPL may be involved with very different pathologies, such
as MS or ITP, as discussed later.
Hypotheses for aPL-mediated thrombosis
Introduction
Many hypotheses purporting to explain why aPL are often
associated with thrombosis or recurrent fetal loss have
been tendered. Some were already indicated, such as inter-
ference with protein C system. This section briefly reviews
other prominent hypotheses, as well as some which are
less well known, such as anti-idiotype network dysregula-
tion. Additional theories are considered in connection
with LA, discussed later. Space limitations preclude dis-
cussion of details of mechanisms, which are found in the
references.
Platelet and/or endothelial activation
Probably the most widely held hypothesis is that some
aPL may activate cells to promote thrombosis. This was
well articulated by Vermylen et al [17] and Arnout [139]
who proposed a two-hit scenario: an initial weak or sub-
clinical activation, such as of platelets, exposing sufficient
anionic PL to favor binding of β2GPI or anti-β2GPI or
other aPL, followed by full-blown thrombotic activation,
possibly involving Fc receptors. Related hypotheses had
been advanced [163-166]. Specific cross-reaction of aPL
with platelet-specific antigens has been reported [167].
Many have proposed a central role for endothelial cells
(EC) as targets of aPL [168-175]. There is little doubt that
the endothelium is centrally involved in APS [176-178].
E-selectin (CD62E) may be a key player in EC activation
[179,180]. Induction of tissue factor (TF) expression in EC
by aPL binding could initiate thrombosis in APS
[181,182].
Our group has reported that chronic platelet activation,
not endothelial activation, distinguishes aPL+ subjects
with history of thrombosis from those without such his-
tory, by two independent measures (p = 0.003, p = 0.001)
[183].
Among the evidences cited by Arnout for initial small
damage being amplified by aPL is that recurrence of APS
tends to affect the same site or vasculature, suggesting that
the site of initial injury is repeatedly targeted. The site of a
pinch injury in mice becomes the site of thrombosis in an
APS animal model [139].
Dueymes et al cites several models of aPL-EC interaction
[184]. Many studies of anti-EC (aEC) independent of aPL
have been published [185-188] but others have consid-
ered aEC in specific relation to aPL [189-193]. These
reports suggest that there is no sharp demarcation
between aPL and aEC or even anti-platelet Ab, since many
PL-binding protein targets are shared by multiple hemat-
opoietic cells, and the surface PL exposed are similar in
the activated state. Heterogeneity of both aEC and aPL has
been observed [194].
Role of complement (C)
The possible role of C in APS is often mentioned in pass-
ing, but a recent review gives more prominence to it [22],
as has Shoenfeld [195]. Fischetti et al, working with an
animal model of APS sensitized with lipopolysaccharide
(LPS) gave persuasive support for a central role of C [196].
Munakata et al showed that C-fixing aCL are specifically
associated with thrombotic events [197]. The role of CJournal of Neuroinflammation 2009, 6:3 http://www.jneuroinflammation.com/content/6/1/3
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may be particularly important in APS with cerebral
ischemia [198]. In general, IgM is more potent than IgG in
fixing complement but this rule varies with subclass, IgG1
= IgG3 > IgG2 > IgG4, and seems to depend on the hinge
region [199]. Thus, IgG subclass could be a determinant of
thrombogenicity by C-fixing aPL.
Hinton suggested that aCL could be a secondary response
to antigens exposed as a result of initial tissue injury
[200]. Antibodies to mitochondria, which are rich in CL
and are not normally exposed, were recently reported
[201]. It was shown in the 1970s that exposure of heart
mitochondria caused C activation [202,203]. Later, Kagi-
yama et al [204] demonstrated that heart mitochondrial
molecules bind and fix C even in absence of IgG, although
normal human plasma contains C-fixing antibodies that
also react. A review of aPL in CAD notes a possible role of
C and cites work by Davis and Brey suggesting a role of C
in stroke [205]. To the extent that APS is C-dependent, the
newly available C-inhibiting drugs may be more effective
than anticoagulation alone.
Recurrent fetal loss (RFL) and complement
RFL is among the diagnostic criteria of APS. Close associ-
ations between RFL and specific aPL have been reported,
some of which were mentioned earlier: aAnV
[97,121,122], IgA aCL [206], aFXII [161], anti-mitochon-
dria [201], aCD36 [207], anti-β2GPI [208,209] and aCL or
protein S deficiency [210]. Shoenfeld and colleagues
exposed rat embryos and placental explants to IgG from
women with RFL, and convincingly demonstrated adverse
effects of CL-dependent anti-β2GPI specifically [211].
Recently, Salmon and colleagues have made what appears
a decisive advance [212]. Using IgG from women with
RFL in a mouse model, they demonstrated an absolute
requirement of C activation for RFL [212]. She concludes
that RFL is an inflammatory condition and that C inhibi-
tors may be the preferred therapy, pointing out that the
efficacy of heparin in APS may rely on its C inhibitory
action. Thus, it is possible that the unifying feature of the
many aPL which have been linked to RFL is the propensity
of a given aPL to fix and activate C, particularly in an
inflammatory setting. Furthermore, C in conjunction with
specific Ab can elicit a wide array of clinical features, and
therefore may be a common denominator in aPL disor-
ders.
Role of cell-derived microparticles (MP)
Zwaal et al suggested that circulating platelet-derived MP
(PMP), which often express phosphatidylserine (PS),
could be players in APS by binding β2GPI or PT to expose
cryptic epitopes for auto-Ab ("neo-autoantigens") [213].
That scenario implies that the platelets are already acti-
vated sufficiently to produce PMP, perhaps the first hit of
a two-hit scenario. Nomura et al showed that some aPL
bind to PMP [214], which is not unexpected since they
express PS. Combes et al later reported on endothelial MP
(EMP) associated with LA [215], and Dignat-George has
further explored the relation of aPL to MP [216]. Vallar et
al reported interaction of β2GPI with PMP [217]. Our lab-
oratory has extensively studied MP from various cell types
and has reviewed PMP and EMP [218,219].
Some authors have been skeptical of the real importance
of MP in thrombosis. However, following work by Hron
et al [220] showing that plasma of patients at risk for
thrombosis have increased thrombin generation, we dem-
onstrated that the increased thrombin generation seen in
those patients resides entirely in the MP fraction [221].
Dysregulation of anti-idiotype network
Cheng et al found that normal sera became positive for
aCL after heating [222], and this has been repeatedly con-
firmed [223,224]. Matsuda et al [225] were unable to rep-
licate results of Chen et al, but McIntyre et al showed that
was caused by the presence of β2GPI in the calf serum
diluent [226], and proposed that all normal subjects have
aPL but normally masked. Cabiedes et al did further inves-
tigations [227]. Kra-Oz et al showed that normal IgG
when purified became aCL+ unless mixed back with nor-
mal sera [228]. Thus, regardless of explanation, it is clear
that many aPL are naturally present but invisible to assays
due to an inhibitor of some kind.
Natural Ab are those normally present and are not masked
if the antigen is not normally present, as in the case of
ABO blood group Abs and others, e.g. [229]. If the antigen
is normally present, the natural autoAb is suppressed,
either by circulating as an immune complex [230] or by
an Ab against the natural Ab, called an anti-idiotype. The
anti-nuclear Ab common in SLE and other autoimmune
disorders are considered to be natural Ab regulated by
anti-idiotypes [231]. The anti-idiotype is usually a
polyspecific IgM [232,233]. However, a variety of inter-
pretations exist.
Natural Ab are important in immune defense [234] and
dysregulation of the normal anti-idiotype network could
explain the emergence of positive aPL in pathological
states. Stahl et al isolated warm-type autoAb causing
autoimmune hemolytic anemia (AIHA) from plasma and
RBC eluates of normal subjects, but the IgM pattern was
different between controls and patients, leading them to
propose that dysregulation of IgM anti-idiotypes causes
the disease [235]. Relatedly, Cabiedes et al detected an
aPC natural autoAb with hemolytic activity in normal
subjects [230]. Moreau et al demonstrated that anti-FVIII
is present in all normal subjects [236].Journal of Neuroinflammation 2009, 6:3 http://www.jneuroinflammation.com/content/6/1/3
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Pan et al showed that normal controls contain SLE-spe-
cific autoAbs which are normally masked [237]. In HIV,
dysregulation of anti-idiotypes has been proposed for the
aPL patterns seen [238]. Interestingly, SLE patients seem
to be protected from HIV/AIDS because they can make an
aCL which neutralizes the virus, deleted in normal sub-
jects as autoreactive [46]. Shoenfeld et al has nicely
reviewed the principles involved [231,239].
A leading hypothesis for the efficacy of intravenous (i.v.)
IgG for APS and other autoimmune diseases is correction
of disrupted anti-idiotype networks. Fischer et al, in an
effort to explain the benefit of i.v. IgG for ITP, found
anti-platelet Ab in the plasma fraction which bound to
i.v. IgG and differed from normal controls, indicating a
role of anti-idiotypes [240]. Yang et al gave evidence for
enhancing Ab in ITP, namely, anti-idiotypes which bind
the Fc portion of the anti-platelet Ab, and proposed this
to account for the difficulty of detecting anti-platelet Ab
in ITP [241]. Three ITP patients who were negative for
anti-platelet antibodies became positive after treatment
with protein A absorption, and the column eluate was
also positive, suggesting that the column treatment
caused separation from a masking anti-idiotype. Thus,
mounting evidence suggests that dysregulation of natu-
ral Ab or anti-idiotype networks may be pivotal to the
expression of aPL.
Other hypotheses
Several other theories have been advanced. McIntyre et al
proposed a pivotal role for anti-kininogen aPL [31]. Yas-
uda et al have demonstrated that monoclonal aCL mark-
edly inhibits fibrinolysis, as does IgG from APS patients,
and proposed a cogent scenario in which impaired fibri-
nolysis is critical to thrombosis in APS [242]. Others have
also implicated defective fibrinolysis, as recently reviewed
[243].
Conclusion
Each of the theories for the putative prothrombotic action
of aPL appears persuasive, and animal studies generally
support them. However, as remarked in a review of theo-
ries based on anti-β2GPI [22], it seems unlikely that they
can all be right. It is ironic that APS was discovered largely
by the aCL test but the clinical value of this test is now
considered marginal, as is anti-β2GPI [70,122]. Neverthe-
less, anti-β2GPI remains the focus of efforts to understand
thrombosis in APS. An alternative viewpoint, increasingly
expressed, is inspired by the multiplicity of target antigens
and clinical presentations: all of the theories may be right
but each may apply only to a particular constellation of
antibodies in a given patient. In this view, we are faced not
with a single disorder, but with a broad spectrum of
autoimmune conditions, not necessarily all thrombo-
genic.
Methodological pitfalls in aPL testing by ELISA techniques
Introduction
It is well recognized that conflicting reports are common
in the literature on aPL detected by ELISA methods. Sev-
eral examples were given in the foregoing survey of aPL
antigens, such as the variable clinical significance of aPT
assay depending on method [106]. Reported prevalence
of aPL in ITP and MS range from negligible to nearly 90%
positive. Reported correlations between a specific pathol-
ogy and any given aPL frequently vary from insignificant
to highly significant. A major cause of these discrepancies
is variables in methods. Many reviews of aPL call attention
to this problem [21,43,244], that of McIntyre et al being
notably detailed [42]. A related problem is frequent fail-
ure to describe details of methods in published reports.
The following comments bring attention to the most eas-
ily overlooked pitfalls. The conclusion to this section fur-
ther explains why this topic is so important.
Plate plastic
Many conflicting reports on anti-β2GPI were cleared up
when it was discovered that β2GPI binds in reactive con-
formation only to polystyrene ELISA plates that have been
treated by gamma radiation [26,245,246]. This was the
case also for aPT [105]. According to McIntyre [42], the
organic solvents used to dissolve PL may also affect the
binding properties. Some authors apply PL from an aque-
ous suspension of sonic-exposed PL [247]. Such details
can spell the difference between positive and negative
result, but are not always reported.
Source and handling of PL
McIntyre et al compared PE from 6 sources and found sig-
nificant differences in assay results [42]; see also [248].
Several studies have shown that positivity for a particular
protein cofactor can depend on whether it is present alone
on the plate or in complex with PL. Thus, not only do
results differ between β2GPI alone vs. β2GPI/CL, but PT
alone on the plate showed no correlation with APS
whereas the complex of PT/PS resulted in good correla-
tion with APS (and LA) [106].
Donohoe et al explored variations of aPT methods and
found conditions where aPT IgM, but not IgG, signifi-
cantly associated with thrombosis [107]. Therefore, con-
trary to many judgments, aPT may indeed have real
clinical significance, but only if assayed in certain ways.
Atsumi et al [106] showed that the clinical relevance of
aPT depends on the method of detection: the complex of
aPT with PS (aPT/PS) was associated with thrombosis but
aPT itself was not.
Drying of the PL should be done under nitrogen but often
is dried in air. McIntyre showed that air causes rapid oxi-
dation of CL to OxCL, and that PS is also prone to oxida-Journal of Neuroinflammation 2009, 6:3 http://www.jneuroinflammation.com/content/6/1/3
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tion, converting to lyso-PS. Thus, many or most aCL
assays actually measure aOxCL, not aCL. Some kits sold as
PE in fact provide lyso-PE [42]. Oxidation of protein anti-
gen on the plate can also affect results [85]. The use of PL
mixtures, intended to save time by detecting more anti-
bodies in a single test [249] effectively dilutes the amount
of each present, reducing sensitivity [42]. Arvieux found
that oxidation of β2GPI caused either enhanced or
decreased binding to Ig: 10 of 20 patients enhanced, 10
decreased [85].
Blocking, washing, dilution
Blockers and diluents include gelatin, non-fat milk, poly-
ethylene glycol (PEG), bovine serum albumin (BSA), fetal
calf serum (FCS), etc., at various concentrations and pH,
with or without EDTA, detergent, and so on. Kilpatrick
compared PEG, BSA and FCS, as well as heat inactivation
of FCS and the effect of solvents [250]. One study of inter-
lab variability listed some of these different practices
[251] but clear conclusions could not be reached owing to
the many variables.
Ming and Fan showed that the neutral detergent, Tween
20, which was, and still is, widely used in ELISA for aPL to
minimize non-specific binding, markedly enhanced the
sensitivity of aCL assay [252]. Cabral et al, for reasons they
could not explain, were unable to replicate that result,
finding the contrary, that Tween 20 reduced or eliminated
detection of aCL, and urged against it [253]. However,
close reading shows that Ming and Fan used Tween only
as a diluent whereas Cabral et al used it to wash the dried
CL three times, probably dissolving most of the CL.
Another report found the effect of Tween 20 useful for dis-
tinguishing aCL that is dependent vs. independent of
β2GPI [254]. Tween is commonly used at concentrations
over a ten-fold range (0.01% to 0.1%), e.g. [251].
Heat inactivation; temperature
Heat inactivation of the serum caused a drop in apparent
aCL titer [250,255]. Most assays are run at room tempera-
ture but some use 37°C. It has been shown that tempera-
ture markedly affects binding of IgG vs. IgM [256].
Heating can inactivate some complement components
and, as earlier mentioned, can unmask some natural anti-
bodies.
Calcium
Many PL-binding proteins require Ca2+ to bind, yet Ca2+ is
rarely present in assays. It has been shown that Ca2+ is an
absolute requirement for assay of aPT [105] but methods
vary. Of two aFVII purified from a patient, one depended
on Ca2+, the other did not [257]. β2GPI binds to PL in a
calcium-dependent fashion despite absence of gla
domains [217], but another study found that Ca2+ (2 mM)
reduced binding to platelet microparticles [217]. Con-
versely, use of EDTA could affect results by extracting
endogenous Ca2+, thereby affecting epitope conformation
of some proteins.
Serum vs plasma
Plasma contains many coagulation factors and other
agents while serum does not, and conversely, serum con-
tains Ca2+  and active proteolytic enzymes. Therefore,
results could differ, depending on the agent tested for.
Wong et al found no difference between plasma and
serum for anti-β2GPI/CL [258] (and pointed out a com-
mon error in statistics). We recently demonstrated gross
differences in assay of CD40L in plasma vs. serum [259],
leading to suspicion of similar effects for at least some
aPL. Freeze-thaw cycles of the sample may also affect sta-
tus of protein-lipid complexes, free proteins, immune
complex, or aggregated IgG.
Calculations: lesson from IgA
Results can differ depending on the cutoff defining a
positive test, e.g. 1, 2, or 3 SD above normal mean, or
more (4 SD [123], 6 SD [125]). The definition of blank
to be subtracted can be even more important, as illus-
trated by some reports on IgA aPL. A large study found
only 2 IgA+ aCL among 795 patients [260]. Close read-
ing, however, reveals that they blocked the CL-coated
plates with FCS and then subtracted the result with FCS
alone (no CL), calling this "non-specific binding"
(NSB), proposed as an important refinement. But the
data showed that NSB varied widely, which is unex-
pected for true NSB, leading to the more likely conclu-
sion that many of the sera were reacting to a component
of the FCS. In contrast, Baleva et al in the following year
[206] found significant IgA aCL in several patient
groups, and in some groups, more IgA than IgG.
Indeed, the authors note that IgA was the only Ig
detected in 8 cases, and cite references compatible with
their findings. A study of aPL in diabetes found that IgA
aPL reacting to PE was more frequent than IgG or IgM
[261]. Thus, one may question the conclusion, widely
repeated, that IgA testing is not useful.
Conclusion
Methodological differences almost certainly accounts for
the majority of conflicting reports. This is important
because deciding the clinical value of a given test, such as
aCL or anti-β2GPI, depends on which reports are believed.
Careful study of methods may reveal the explanation for
discrepancies. For the same reason, one must be suspi-
cious of meta-analyses which, in effect, average together a
large number of reports, thereby nullifying those which
are favorable. Galli et al acknowledge this point in the
concluding sentence of their abstract [244], and others
have commented similarly [262,263]. To address this
problem, many workshops aimed at standardizing meth-Journal of Neuroinflammation 2009, 6:3 http://www.jneuroinflammation.com/content/6/1/3
Page 10 of 21
(page number not for citation purposes)
ods have been held [251,264,265], as recently discussed
[266]. Standard methods are clearly mandatory for clini-
cal testing, although problems have persisted [248,267].
However, this could be counter-productive since variant
methods may give more favorable results for a particular
antigen or clinical condition. For research purposes,
important discoveries could critically depend on variant
methods, as illustrated by some of the examples cited.
Future technology may enable dozens of assays per
patient, easily and cheaply, by robotic arrays.
The lupus anticoagulant (LA)
Background: The LA paradox
As its name implies, the LA acts in vitro like an anticoagu-
lant, prolonging the activated partial thromboplastin time
(APTT) or other tests specifically designed to detect it.
According to a 1961 review [268], this effect was first
reported in 1946 in a patient with ITP [269]. Its frequent
association with SLE was reported in a series of papers by
Conley and colleagues from 1948 [270] to 1952 [2]. Both
papers cited describe LA in the setting of hemorrhagic dia-
theses, as expected of an anticoagulant. The latter is usu-
ally cited as the origin of the LA test, although the name,
LA, was not coined until 1972.
However, Bowie et al in 1963 described four cases of SLE
with thrombosis despite presence of LA [271]. This was
the first clear statement of the paradox: why should throm-
bosis occur in the presence of an anticoagulant? Efforts to
answer this persist to the present.
Subsequently, a growing number of reports through the
1970s found association of LA with thrombosis at greater
frequency than hemorrhage, culminating with recogni-
tion of the aPL syndrome (APS) in the mid-1980s, as ear-
lier referenced [3-5,272].
Principles of LA testing
Although the LA is widely spoken of as an aPL, it must be
stressed that LA is not defined by any specific antibody or
other known agent, but only by its effect in an LA assay. In
its simplest early form, the LA assay was the recalcification
time (recal time) of platelet-poor plasma (PPP), together
with the "platelet neutralization test" (PNT) for confirma-
tion [268]. Briefly, one adds sufficient calcium to over-
come the citrate in the PPP and observes if the time to
coagulation is abnormally long, indicating LA+, provided
that in addition, the prolongation is reduced by the PNT
(originally, addition of platelets or platelet membranes).
This was interpreted to mean that some factor in the
plasma, called the LA, was acting to block sites on the
phospholipids (PL) essential for coagulation, suggesting
that aPL is that factor. The rationality of the PNT is that an
excess of PL overwhelms the ability of the LA to block
enough sites to prolong the time. A variety of LA tests are
now in use, beyond the scope of this review, but all are
similar in principle.
LA associates best with thrombosis
Among the first persuasive reports of a strong association
between LA and thrombosis was the retrospective analysis
of Mueh at al in 1980 [273]. Following recognition of the
syndrome, APS, it became common to test LA in parallel
with solid-phase ELISA of aPL, leading to several reports
showing that LA has a stronger association with thrombo-
sis than aPL measured by ELISA, notably by Derkens et al
in 1988 [274], later confirmed repeatedly [6,275-277],
explicitly stated by Horbach et al in 1996 [278] and by
Arnout in 2001 [11] and, if further confirmation was
needed, in a meta-analysis by Galli in 2003 [244]. Indeed,
several studies found that thrombosis associated closely
with LA but poorly or not at all with aPL by ELISA, e.g.
[276,277].
Thus, it is firmly established that the association of LA+
assay with thrombophilic states is much stronger than
ELISA of aPL such as aCL, anti-β2GPI, or other. Further-
more, this association is robust with respect to variant
methods. However, if it is true that LA is an aPL, we are
faced with the problem of explaining why LA correlates so
much better with thrombosis than aPL measured by
ELISA.
What is the LA? Why thrombogenic?
As explained by Triplett [7], early results of Harris et al [3]
suggested to them that LA and aCL were one and the same
entity. This was later shown to be incorrect since the two
were clearly separable. Nevertheless, the assumption con-
tinued that LA is a manifestation of aPL, to the point
where LA is spoken of almost as a synonym for aPL, or as
a particular type of aPL [279]. Indeed, Triplett has stated
that LA is an aPL, by definition [7].
As detailed in several reviews, such as by Arnout [11], it
has been shown that at least some LA are in fact expres-
sions of anti-β2GPI. Roubey et al showed that LA plasma
added to normal plasma prolonged coagulation but not if
the plasma was first depleted of β2GPI [279]. Around the
same time, Arvieux showed that mouse antibodies against
β2GPI had LA-like activity [280]. Arnout made a series of
monoclonal antibodies (mAb) against β2GPI and found
that only 7 of 21 mAb had LA activity, variable in degree,
one being very strong [28,281]. This suggested that the
epitope targeted was critical for LA activity.
According to Arnout [11], the now accepted explanation
for the LA activity of anti-β2GPI was developed by three
groups, Willems at al in 1996 [282]), Takeya et al in 1997
[283], and Arnout et al in 1998 [28]. The essence of it is
that only those anti-β2GPI which can bind two moleculesJournal of Neuroinflammation 2009, 6:3 http://www.jneuroinflammation.com/content/6/1/3
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of β2GPI (divalently) in the soluble phase cause enhanced
binding to PL and exhibit LA activity [11]. However, not
all LA depend on β2GPI.
In the same timeframe, others had shown that aPT can
also exert LA activity, notably Bevers et al and Galli et al in
1992 [284], Oosting et al in 1993 [72], and Permpikul et
al in 1994 [285], as referenced [7,11]. A method was
devised to discriminate between LA that depended on PT
from LA that depended on β2GPI [286]. The explanation
given for why some but not all aPT exhibit LA activity is
similar to that given for anti-β2GPI. This explanation does
not, however, directly account for thrombosis, except by
way of the hypotheses listed above for aPL in general.
Field et al [287,288] in their introduction give references
to about five different theories for LA but dismiss them all
as unconvincing, and then supply evidence for a novel
explanation of their own: IgG from LA plasma inhibits
thrombin generation only under static conditions,
whereas under the shearing conditions of natural blood
flow, LA promotes thrombin generation. In that scenario,
the LA effect is an in vitro artifact.
Several workers have proposed anti-annexin V (aAnV) as
the agent of LA, with direct bearing on thrombosis. Mat-
suda et al found that aAnV was common in SLE patients
(positive in 12 of 47) and associated strongly with LA
activity [123]; for commentary, see [124]. The LA activity
of aAnV was further explored by Nakamura et al the next
year [90]. It is possible that aAnV may also bear on the
antagonism between annexins and phospholipase A2
(PLA2) [126].
In a series of papers, Rand et al has proposed to resolve the
LA paradox on the basis of competition between aPL and
the natural anticoagulant function of AnV [289-291].
They showed that aPL IgG inhibits the anticoagulant effect
of exogenously added AnV. However, the strong action of
added AnV is contrary to the hypothesis that AnV is natu-
rally present in plasma in significant amounts. Although
AnV exhibits an effect on coagulation indistinguishable
from LA [112], it has not been shown to play a significant
role as a natural anticoagulant, except perhaps in preg-
nancy.
Most reviewers now accept the existence of multiple LA,
not necessarily limited to anti-β2GPI, aPT and/or aAnV.
For example, anti-FVIII behaves like LA [292]. A study of
LA+ patients found that all of them reacted to at least one
pure PL, and 95% were positive for aPE [146]. The specific
antigen(s) was not identified. We have speculated that
TFPI (the inhibitor of tissue factor) could exhibit LA activ-
ity, since it prolongs coagulation, could be neutralized by
excess PL, and in at least some circumstances, is elevated
in thrombophilic state [293]. Thus, quite different expla-
nations are conceivable.
Conclusion
Although it has been clearly shown that some aPL exhibit
LA activity, and have pathological effects in animal mod-
els, the specific identity of the LA relevant to thrombosis
is unknown in many cases. Moreover, why LA associates
so much better with thrombosis compared to aPL test by
ELISA remains an open question. As deLaat et al wrote in
2007, the association of LA with thrombosis is "for yet
unknown reasons" [291].
Antiphospholipid antibodies (aPL) in non-APS, non-SLE 
disorders
It has long been recognized that aPL occur at high fre-
quency in many disorders other than APS and SLE, espe-
cially those known to be immune-mediated, such as
immune thrombocytopenic purport (ITP), multiple scle-
rosis (MS), and rheumatoid arthritis (RA). However, the
significance of aPL in these disorders has been generally
dismissed as non-specific or epiphenomenal, partly
because the aPL did not appear to be related to symptoms,
and perhaps also because aPL in these disorders is incon-
sistent with the paradigm that the pathological signifi-
cance of aPL is limited to thrombosis. This review was
motivated in part by recent findings which indicate that
aPL are in fact associated with symptoms in non-APS,
non-SLE disorders in humans.
Multiple sclerosis (MS)
MS is an inflammatory disorder believed to be autoim-
mune in etiology, and can present with features resem-
bling APS [294-297]. Several reviews of the neurological
symptoms of APS/SLE are available [298-300], and many
case reports, e.g., cerebral ischemia [301]. However, MS is
not thought to involve ischemia, although elements of the
coagulation cascade are present in MS lesions, including
fibrinogen and recently, tissue factor and protein C inhib-
itor [302].
In 2000, our collaborative investigation demonstrated
elevated endothelial microparticles (EMP) during exacer-
bations of MS [303,304]. Those findings motivated fur-
ther investigations, this time of aPL in MS, with the
hypothesis that aPL might be involved in endothelial acti-
vation in MS. Several prior reports had established that
aPL commonly occur in MS, but in most of them the
patient population was heterogeneous or inadequately
defined, and there was no indication of a relation between
aPL and the pathophysiology of MS.
To examine the relationship more closely, we tested sam-
ples of well-defined, treatment-naive MS patients in either
exacerbation or remission, documented by neurologicalJournal of Neuroinflammation 2009, 6:3 http://www.jneuroinflammation.com/content/6/1/3
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as well as brain MRI with and without contrast. The cen-
tral finding was that all aPL measured were significantly
elevated in acute phases vs.  remission, and correlated
strongly with MRI imaging, p = 0.002 [136]. The antigens
tested included β2GPI, FVII, and four pure PL (CL, PC, PS,
PE). Of interest, aFVII was never detected in remission but
was present in 60% of acute MS; and anti-β2GPI was pos-
itive in 80% of acute MS. It is possible that unidentified
and possibly MS-specific auto antibodies were also
present, judging by the strong reaction to the pure PL in
acute, but not remission, cases. Unexpectedly, aPL in MS
were exclusively of IgM class, with no IgG detected.
Because that work showed a direct relation between aPL
and clinical state in MS, it is plausible to suspect that aPL
may be involved in the pathogenesis of MS. Of course, the
possibility exists that aPL in acute MS are epiphenomenal;
but the same argument could be levelled against the
hypothesis that aPL cause thrombosis. In further support,
Shoenfeld and colleagues clearly demonstrated neu-
ropathological effects of aPL in animal models [305-307].
Since some aPL have been identified with anti-endothelial
(anti-EC) antibodies (earlier cited), and since our group
[303] and others have documented endothelial activation
in MS, it is relevant to note that anti-EC have been
detected in MS and were proposed to contribute to its
pathogenesis. In 1989, Tsukada et al. found anti-EC in
75% of active MS but in only 4% of remission [308].
However, a 1992 report found only 13% positive [309]
and a later report found only 10% reactive to human
umbilical vein EC (HUVEC) [310]. On the other hand,
another report around the same time, but using brain
microvascular EC rather than HUVEC, found that 12/16
active vs 0/15 inactive MS reacted to EC [311]. This sug-
gests that anti-EC in MS are specific for brain microvessels,
and would be consistent with the fact that CNS lesions in
MS tend to develop around brain microvessels (Dawson
fingers) [312]. Thus, brain-specific anti-EC could be a piv-
otal pathogenic mechanism of aPL in MS.
Immune thrombocytopenic purpura (ITP)
As with MS, it was long known that aPL commonly occur
in ITP, but no one had related their presence to clinical
state (low platelets, bleeding), therefore their presence
was dismissed as inconsequential. Y.S. Ahn, a specialist in
ITP, had drawn attention to cerebral ischemia sometimes
associated with ITP, particularly in splenectomized
patients, leading to vascular dementia [313].
To investigate if aPL might be involved, we studied series
of patients stratified by clinical state (acute, chronic,
remission) and demonstrated, for the first time, a clear
association between elevated aPL and onset of acute
symptoms [314]. Sequential study of six cases confirmed
the general conclusion, that aPL rise with exacerbations
and decline or disappear in remission of ITP. Unexpect-
edly, however, no relation was detected between aPL/LA
and those patients with ITP-associated cerebral ischemia.
In a follow-up study, Bidot and colleagues [315] com-
pared aPL patterns in APS vs.  active ITP (remission
excluded). One notable difference was that LA was absent
in all ITP patients but was present in 24/33 (79%) of APS.
This supports the unique significance of LA in thrombosis.
IgG anti-β2GPI was >3-fold more common in APS than
ITP, but positive reaction to the pure PL (CL, PC, PS, PE)
was more common in ITP, p < 0.05. This need not imply
that aPL in ITP are mainly of the so-called non-pathogenic
type, since it is possible that the pure PL are reacting to
unidentified antigens in the plasma, as they would to
platelet membranes.
Since CD36 is often found in association with aPL, it is
apropos to mention our findings on CD36 in ITP. On
platelets, this antigen is known as glycoprotein IV (GpIV),
and was of interest to us in thrombotic thrombocytopenic
purpura (TTP) [316] and other thrombosis [317]. More
recently, we found that aCD36 (and some other anti-
platelet autoantibodies) is more commonly elevated in
ITP patients with bleeding symptoms than in comparable
patients without bleeding (unpublished), unexpected
since aCD36 is usually associated with thrombosis, as ear-
lier mentioned.
HIV/AIDS
A viral cause of APS has been proposed [318]. HIV infec-
tion carries a high frequency of aPL [34,319] but here, too,
the aPL in HIV were considered to be of the infection-
related type and non-pathogenic. Haynes et al [46] point
out that anti-HIV antibodies mounted by most patients
fail to neutralize the virus, but a rare few do mount neu-
tralizing responses, and those studied turned out to be
polyspecific aCL, similar to the aPL profile seen in lupus
(SLE). Indeed, they cite references indicating that SLE
patients appear to be protected against contracting HIV,
and argue that the general population fails to make such
aPL because they have been deleted from the repertoire as
self-reactive. In support of their contention, one of the
neutralizing anti-HIV they studied was autoreactive with
dsDNA, centromere B, histones and other self targets [46].
Relatedly, Zhang et al [320] investigated why most people
fail to mount effective immune responses to HIV envelope
proteins (Env), and suggested that Env suppresses CD40L
expression, which in turn blunts the T cell ability to acti-
vate DCs. However, we feel that findings of Zhang et al
[320] are consistent with the scenario given by Haynes et
al [46]. Specifically, the aPL seen in the context of HIV and
other infections may be more than epiphenomena and
could offer important clues to immune function.Journal of Neuroinflammation 2009, 6:3 http://www.jneuroinflammation.com/content/6/1/3
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Conclusion
The thrust of this review has been to highlight some of the
uncertainties and challenges in the field. To begin with,
the proliferation of target antigens over the last 20 years
has greatly broadened the classical concept of "aPL," and
calls into question the definition of aPL. The strength of
the association of aPL (measured by ELISA) with throm-
bosis has been questioned, but this depends on which
reports are believed. On the other hand, there is no doubt-
ing the close association of LA with thrombosis; but
exactly why this is true remains unsettled. Finally, new evi-
dence is presented indicating that aPL may be involved
with the pathogenesis of other disorders, notably MS and
ITP, as distinct from the role of aPL exclusively in throm-
bosis.
The picture now emerging is that aPL are part of a large
spectrum of autoantibodies, including, for example, those
of ITP, and that APS is just one manifestation of a partic-
ular constellation of aPL. We may be better served by
abandoning the concept that aPL are exclusively thrombo-
genic.
In regard to the cause of aPL-associated pathologies, a
promising hypothesis is dysregulation of anti-idiotype
networks. Many of the consequences appear to be best
explained in terms of complement-mediated effects.
However, full understanding of the aPL phenomenon
remains a challenge for the future.
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